Lab automation group Stratec falls after guidance cut
** Shares of Stratec SBSG.DE fall as much as 6.7% after the German lab automation group cut its 2024 sales guidance after market close on Thursday
** After weaker than expected preliminary 9-mth sales due to postponed deliveries into Q4 and 2025, Stratec expects 2024 sales to "remain stable or decline slightly" from last year, vs previous guidance for stable to slightly higher sales
** It confirms EBIT margin guidance and says it is "shortly due to sign further additional orders" that should improve Q4 results, which a local trader says sounds "quite cryptic"
** "The Q3 print is a reminder of the lumpy nature of the in vitro diagnostics (IVD) instrument sector, which can mean a few order delays resulting in notable deviations from management and consensus expectations," Berenberg analyst Odysseas Manesiotis says
** However, Manesiotis adds the guidance cut does not "notably" change the consensus which was already expecting flat sales and margin at the lower end of the group's 10-12% target
** The shares are down 2% by 0825 GMT, after touching their lowest price since Aug. 6 at 37.10 euros earlier in the session
Reporting by Marleen Kaesebier
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
